| Literature DB >> 33610731 |
Radha Munagala1, Farrukh Aqil2, Jeyaprakash Jeyabalan1, Raghuram Kandimalla3, Margaret Wallen1, Neha Tyagi3, Sarah Wilcher4, Jun Yan5, David J Schultz6, Wendy Spencer1, Ramesh C Gupta7.
Abstract
Gene therapy promises to revolutionize biomedicine and personalized medicine by modulating or compensating the expression of abnormal genes. The biggest obstacle for clinical application is the lack of an effective, non-immunogenic delivery system. We show that bovine colostrum exosomes and polyethyleneimine matrix (EPM) delivers short interfering RNA (siRNA) or plasmid DNA (pDNA) for effective gene therapy. KRAS, a therapeutic focus for many cancers, was targeted by EPM-delivered KRAS siRNA (siKRAS) and inhibited lung tumor growth (>70%) and reduced KRAS expression (50%-80%). Aberrant p53 is another therapeutic focus for many cancers. EPM-mediated introduction of wild-type (WT) p53 pDNA (pcDNA-p53) resulted in p53 expression in p53-null H1299 cells in culture, subcutaneous lung tumor, and tissues of p53-knockout mice. Additionally, chemo-sensitizing effects of paclitaxel were restored by exogenous WT p53 in lung cancer cells. Together, this novel EPM technology represents an effective 'platform' for delivery of therapeutic nucleic acids to treat human disease.Entities:
Keywords: Cancer; Delivery; Exosome; Plasmid-DNA; siRNA
Mesh:
Substances:
Year: 2021 PMID: 33610731 PMCID: PMC8005491 DOI: 10.1016/j.canlet.2021.02.011
Source DB: PubMed Journal: Cancer Lett ISSN: 0304-3835 Impact factor: 8.679